Ankündigung • Mar 27
EuBiologics Co., Ltd. (KOSDAQ:A206650) announces an Equity Buyback for KRW 6,000 million worth of its shares. EuBiologics Co., Ltd. (KOSDAQ:A206650) announces a share repurchase program. Under the program, the company will repurchase up to KRW 6,000 million worth of its common stock pursuant to an agreement with NH Investment & Securities. The purpose of the program is stabilization of stock price and enhancement of shareholder value. The program will expire on September 30, 2026. As of March 25, 2026, the company had 0 shares available for acquisition within the dividend-eligible range and 0 shares from other stocks. Ankündigung • Mar 07
EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2026 EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 125, wonmudong-gil, gangwon-do, chuncheon South Korea Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₩16,200, the stock trades at a trailing P/E ratio of 23.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 98% over the past three years. New Risk • Feb 04
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Feb 03
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩13,820, the stock trades at a trailing P/E ratio of 20.4x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 58% over the past three years. Valuation Update With 7 Day Price Move • Nov 14
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩13,990, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 16x in the Biotechs industry in South Korea. Total returns to shareholders of 22% over the past three years. New Risk • Mar 20
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company. Ankündigung • Mar 08
EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2025 EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 125, wonmudong-gil, dongsan-myeon, gangwon-do, chuncheon South Korea New Risk • Oct 05
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. New Risk • Aug 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩20b free cash flow). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change). Ankündigung • Jul 15
Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 Trial POP Biotechnologies announced top line interim results of a Phase 3 clinical trial of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics. EuCorVac-19 is a protein-based vaccine consisting of a vaccine antigen displayed on immunogenic nanoparticles, using POP BIO's Spontaneous-nanoliposome antigen particle (SNAP) technology. The phase 3 trial of EuCorVAC-19 was conducted in the Philippines in approximately 2,600 adults (NCT05572879). EuCorVac-18 demonstrated superior antibody immunogenicity compared to a World Health Organization Emergency Use Authorized adenoviral vector vaccine, thereby meeting the primary endpoint of the phase 3 trial. The formation of neutralizing antibodies, which prevent COVID-19 infection, was more than twice as high in EuCorVac- 19 compared to the control vaccine. EuCorVac-20 exhibited a high serological response rate with neutralizing antibody titers increasing after vaccination. In particular, the neutralizing antibody titers and serum response rates in subjects aged over 65 exceeded those of the control vaccine. EuCorVac-19's safety profile was further established in this phase 3 study. EuCorVac-19 showed a slightly lower incidence than the control vaccine of solicited adverse events and there was no difference between EuCorVac-19 and the control vaccine in the incidence of unsolicited adverse events. These results further validate the strength and synergy of POP BIO's SNAP and EuBiologics' EuIMT platform technologies used in the EuCorVac-19 vaccine. Further development of booster vaccines, new strain vaccines, and combination vaccines for COVID-19 will be significantly more straightforward in the future. EuCorVac-19 was already shown to be safe and immunogenic in a Phase I/II clinical trial, the results of which were announced in December 2021. The Philippine Phase 3 trial, conducted since third quarter of 2022, were supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the ministry of Health & Welfare, Republic of Korea. Based on the results of this clinical study, EuBiologics plans to apply for product approval in the Philippines shortly. Later this year, results will become available from a second independent Phase 3 clinical study being carried out in the Democratic Republic of Congo. Ankündigung • Feb 04
Eubiologics Co., Ltd. Announces Phase Iii Clinical Trial Ind Approval of Eucorvac-19, Covid-19 Vaccine Candidate, in South Korea EuBiologics Co., Ltd. announced on Jan. 28 that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, obtained approval to conduct Phase III comparison clinical trials from the Ministry of Food and Drug Safety in South Korea. Eubiologics is able to commence Phase III comparison trial for 4,000 healthy participants including the Philippines, Bangladesh and other countries based on the standard comparison clinical trial guideline by the Ministry of Food and Drug Safety in Korea. Eubiologics will work closely with the global CROs for recruiting the participants to expedite the entire process in low vaccination rate countries and will also expedite the trial result analysis to advance EuCorVac-19’s regulatory approval and commercialization. Eubiologics is developing EuCorVac-19, its vaccine platform, which consists of owned antigen, EulMT in-licensed from Korea Institute of Science and Technology and SNAP technology of POP Biotechnologies that EuBiologics has invested. The company has announced Phase I/II trial interim results in December 2021. On the other hand, as EuCorVac-19 has already proved its safety and efficacy through Phase I/II clinical trial, the company expects to expedite the development of Omicron variant vaccine based on the same platform used for EuCorVac-19. Currently, the pre-clinical trial of Mouse immunogenicity test and TG mouse which is transformed from human gene are under progress and the company plans to proceed with the human trial within the 1st half of 2022. In addition, a booster vaccine is necessary due to the dominance of the Omicron variant, and thus the company will commence its trial to prove efficacy as a booster vaccine. Eubiologics has 2 main animal-based bioreactors to produce recombinant protein antigens at Chuncheon Plant 1 and EcML which is adjuvant at Chuncheon Plant 2. The total capacity of COVID-19 vaccine is from 100M to 200M doses per year. EuCorVac-19 vaccine uses the same type of cell line which is for antibody treatment, so if the company uses these facilities, its manufacturing capacity can be further expanded. Eubiologics has already received funds for Phase I/II March 2021 from the new drug development committee of the Ministry of Health and Welfare in Korea and recently submitted the application for phase III trial to get additional financial assistance. Is New 90 Day High Low • Feb 18
New 90-day low: ₩17,300 The company is down 1.0% from its price of ₩17,450 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 2.0% over the same period. Ankündigung • Feb 10
EuBiologics Co., Ltd., Annual General Meeting, Mar 25, 2021 EuBiologics Co., Ltd., Annual General Meeting, Mar 25, 2021, at 10:00 Korea Standard Time. Ankündigung • Jan 22
EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea EuBiologics announced on January 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial. The Phase I trial is designed for 50 healthy adults aged from 19 to 50 years old and will be conducted at ‘the Catholic University of Korea Eunpyeong St. Mary’s Hospital’ evaluating safety, tolerance and immunogenicity. The Phase II trial will be subsequently carried out for 230 adults aged from 19 to 75 years old in four hospitals located in Seoul metropolitan area in order to evaluate dosage and vaccine immunogenicity. EuCorVac-19 under development by EuBiologics is a safe vaccine formulated with the coronavirus spike protein using the recombinant protein technology and with a potent adjuvant, similar to the other virus vaccines already licensed in the world. EuCorVac-19 is a liquid injection in glass vials and can be stored and distributed at refrigerated temperatures which can take advantage of the general distribution system for biopharmaceuticals. EuBiologics plans to consult with the Korean Ministry of Food and Drug Safety in order to progress the Phase III clinical trial later this year based on the interim results of the Phase I/II trial available no later than June 2021 and receive an emergency use approval of EuCorVac-19, as early as possible. EuBiologics also has a GMP accredited facility which can manufacture recombinant protein antigens and adjuvants, with confidence to provide competitive pricing. Is New 90 Day High Low • Jan 04
New 90-day high: ₩22,350 The company is up 3.0% from its price of ₩21,800 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 18% over the same period. Is New 90 Day High Low • Nov 12
New 90-day low: ₩16,000 The company is down 9.0% from its price of ₩17,500 on 14 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 5.0% over the same period. Is New 90 Day High Low • Oct 26
New 90-day low: ₩16,300 The company is down 7.0% from its price of ₩17,450 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 12% over the same period. 